search button

Phase II study of erlotinib for previously treated patients with EGFR wild‑type non‑small‑cell lung cancer, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System

  • Authors:
    • Masahiro Morise
    • Hiroyuki Taniguchi
    • Hideo Saka
    • Joe Shindoh
    • Ryujiro Suzuki
    • Eiji Kojima
    • Tetsunari Hase
    • Masahiko Ando
    • Masashi Kondo
    • Hiroshi Saito
    • Yoshinori Hasegawa

  • View Affiliations

  • Published online on: July 22, 2014     https://doi.org/10.3892/mco.2014.354
  • Pages: 991-996
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

While assessing the efficacy of erlotinib in patients with epidermal growth factor receptor (EGFR) wild‑type (WT) non‑small‑cell lung cancer (NSCLC), the sensitivity of the method used for the EGFR mutation analysis may affect the evaluation of the efficacy. We conducted a phase II study of erlotinib for previously treated patients with EGFR WT NSCLC screened by the peptide nucleic acid‑locked nucleic acid (PNA‑LNA) polymerase chain reaction (PCR) clamp method, which is known to be highly sensitive. The primary endpoint was the objective response rate (ORR). Preplanned reevaluation of the EGFR genotype as an exploratory endpoint was performed using the Scorpion amplification refractory mutation system (S‑ARMS) assay. Erlotinib was administered daily until disease progression or development of unacceptable toxicity. A total of 53 evaluable patients were enrolled. The histological subtypes were adenocarcinoma in 40 patients, squamous cell carcinoma in 9 patients and not otherwise specified NSCLC in 4 patients. Partial response (PR) was achieved in 6 patients (4 with adenocarcinoma and 2 with squamous cell carcinoma). The ORR was 11.3% [95% confidence interval (CI): 4.3‑23.0]. The median progression‑free survival (PFS) was 1.8 months (95% CI: 1.2‑2.3). Samples from 26 of the 53 patients (49.0%) were available for EGFR mutation reanalysis with the S‑ARMS assay. Of these 26 samples, only 1 sample of adenocarcinoma was found to be EGFR mutation‑positive (exon 19 deletion) and the patient achieved a PR. The EGFR WT genotype was reconfirmed by the S‑ARMS assay in the remaining 25 patients and 2 of these patients exhibited a PR. This study did not meet the primary endpoint, although erlotinib was found to be moderately effective in pretreated patients with EGFR WT NSCLC, even when the EGFR mutational status was confirmed by the highly sensitive PNA‑LNA clamp PCR method.
View Figures
View References

Related Articles

Journal Cover

November-December 2014
Volume 2 Issue 6

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 1.2
  • Ranked
    (total number of cites)
  • CiteScore: 2.6
  • CiteScore Rank: Q3: #242/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.693
  • SCImago Journal Rank (SJR): 0.393
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Morise M, Taniguchi H, Saka H, Shindoh J, Suzuki R, Kojima E, Hase T, Ando M, Kondo M, Saito H, Saito H, et al: Phase II study of erlotinib for previously treated patients with EGFR wild‑type non‑small‑cell lung cancer, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System. Mol Clin Oncol 2: 991-996, 2014
APA
Morise, M., Taniguchi, H., Saka, H., Shindoh, J., Suzuki, R., Kojima, E. ... Hasegawa, Y. (2014). Phase II study of erlotinib for previously treated patients with EGFR wild‑type non‑small‑cell lung cancer, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System. Molecular and Clinical Oncology, 2, 991-996. https://doi.org/10.3892/mco.2014.354
MLA
Morise, M., Taniguchi, H., Saka, H., Shindoh, J., Suzuki, R., Kojima, E., Hase, T., Ando, M., Kondo, M., Saito, H., Hasegawa, Y."Phase II study of erlotinib for previously treated patients with EGFR wild‑type non‑small‑cell lung cancer, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System". Molecular and Clinical Oncology 2.6 (2014): 991-996.
Chicago
Morise, M., Taniguchi, H., Saka, H., Shindoh, J., Suzuki, R., Kojima, E., Hase, T., Ando, M., Kondo, M., Saito, H., Hasegawa, Y."Phase II study of erlotinib for previously treated patients with EGFR wild‑type non‑small‑cell lung cancer, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System". Molecular and Clinical Oncology 2, no. 6 (2014): 991-996. https://doi.org/10.3892/mco.2014.354